Olanzapine effects on auditory sensory gating in schizophrenia

American Journal of Psychiatry

Volumn 160, Issue 11, 2003, Pages 2066-2068

  Arango, Celso ^a   Summerfelt, Ann ^a   Buchanan, Robert W ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; FLUPHENAZINE; HALOPERIDOL; OLANZAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EVOKED AUDITORY RESPONSE; HUMAN; LATENT PERIOD; PRIORITY JOURNAL; RELAPSE; SCHIZOPHRENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ACOUSTIC STIMULATION; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; AUDITORY PERCEPTION; BENZODIAZEPINES; EVOKED POTENTIALS, AUDITORY; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; SCHIZOPHRENIA; STARTLE REACTION;

EID: 4744362026     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.11.2066     Document Type: Article

References (12)

1. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R: Schizophrenia, sensory gating, and nicotinic receptors Schizophr Bull 1998; 24:189-202
2. Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R: Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 1992; 32:607-616
3. Adler LE, Hoffer LD, Wiser A, Freedman R: Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993; 150:1856-1861
4. Buchanan RW, Summerfelt A, Tek C, Gold J: An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 2003; 59:29-33
5. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, Freedman R: Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry 1996; 40:181-188
6. Nagamoto HT, Adler LE, McRae KA, Huettl P, Cawthra E, Gerhardt G, Hea R, Griffith J: Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4- hydroxyphenylglycol. Neuropsychobiology 1999; 39:10-17
7. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL Normal P50 suppression m schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry 2000, 157:767-771
8. Yee CM, Nuechterlein KH, Morris SE, White PM: P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J Abnorm Psychol 1998; 107:691-698
9. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14:87-96
10. Adler LE, Waldo MC, Tatcher A, Cawthra E, Baker N, Freedman R: Lack of relationship of auditory gating defects to negative symptoms in schizophrenia. Schizophr Res 1990; 3:131-138
11. Yee CM, Nuechterlein KH, Morris SE, White PM: P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J Abnorm Psychol 1998; 107:691-698
12. Conley RR, Tamminga CA, Kelly DL, Richardson CM: Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry 1999; 46:73-77